Pituitary Carcinoma: Rare Disease with Difficult Diagnosis and Treatment

Although pituitary tumours are common, pituitary carcinomas are very rare. They are defined as adenohypophyseal tumours with metastatic activity within and outside the boundaries of the central nervous system (CNS). They usually spread to the other parts of the body, by the time they are diagnosed. Because so few cases of pituitary carcinoma have been reported worldwide, it is difficult to learn much about them, and it is difficult to diagnose and treat them. Pituitary carcinomas cannot be distinguished from benign pituitary tumours only on the basis of clinical findings and imaging. Presence of metastases is indicative of carcinoma. Many molecular markers for pathogenesis have been proposed, but none so far is a reliable predictor of disease progression or outcome. Treatment for pituitary carcinomas includes surgery, radiotherapy, and chemotherapy. The paucity of reported cases and literature on pituitary carcinomas renders necessary further research into underlying mechanisms, diagnostic findings, and novel molecular targets for therapy.

[1]  O. Mete,et al.  Overview of the 2017 WHO Classification of Pituitary Tumors , 2017, Endocrine Pathology.

[2]  R. Vogel,et al.  Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports. , 2016, Neuro-oncology practice.

[3]  Antonio Di Ieva,et al.  Aggressive pituitary adenomas—diagnosis and emerging treatments , 2014, Nature Reviews Endocrinology.

[4]  A. Wierinckx,et al.  Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management , 2013, Pituitary.

[5]  S. Kunwar,et al.  Clinical management of pituitary carcinomas. , 2012, Neurosurgery clinics of North America.

[6]  G. Luzardo,et al.  What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? , 2012, Hormones.

[7]  F. Ducray,et al.  New targeted therapies in pituitary carcinoma resistant to temozolomide , 2012, Pituitary.

[8]  J. Honegger,et al.  Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature. , 2011, The Journal of clinical endocrinology and metabolism.

[9]  J. Welsh,et al.  Pituitary Adenoma: A Radiotherapeutic Perspective , 2010, American journal of clinical oncology.

[10]  P. Chanson,et al.  Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. , 2010, Endocrine-related cancer.

[11]  H. Hammes,et al.  SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[12]  B. Scheithauer,et al.  Silent subtype 3 carcinoma of the pituitary: a case report , 2010, Neuropathology and applied neurobiology.

[13]  B. Scheithauer,et al.  Ki-67 in pituitary neoplasms: a review--part I. , 2009, Neurosurgery.

[14]  A. Falini,et al.  Tumours , 2008, Neurological Sciences.

[15]  B. Scheithauer,et al.  P53 Gene Mutations in Pituitary Carcinomas , 2007, Endocrine pathology.

[16]  Michael Buchfelder,et al.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. , 2007, European journal of endocrinology.

[17]  PhD George Kontogeorgos MD Classification and pathology of pituitary tumors , 2007, Endocrine.

[18]  B. Scheithauer,et al.  Pathobiology of Pituitary Adenomas and Carcinomas , 2006, Neurosurgery.

[19]  S. Melmed,et al.  Pathophysiology of pituitary adenomas. , 2005, Journal of endocrinological investigation.

[20]  M. Buchfelder,et al.  Clinical review: Diagnosis and management of pituitary carcinomas. , 2005, The Journal of clinical endocrinology and metabolism.

[21]  A. Grossman,et al.  Malignant Pituitary Tumours , 1998, Pituitary.

[22]  A. Grossman,et al.  Stereotactic radiosurgery XVI: a treatment for previously irradiated pituitary adenomas. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  S. Asa,et al.  The pathogenesis of pituitary tumours , 2002, Nature Reviews Cancer.

[24]  R. E. Peterson,et al.  Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  T. Arzberger,et al.  Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report. , 2002, European journal of endocrinology.

[26]  J. J. Mukherjee,et al.  The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[27]  F. Meyer,et al.  Symptomatic pituitary metastases. , 1998, Journal of neurosurgery.

[28]  R. Fahlbusch,et al.  In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. , 1994, The Journal of clinical endocrinology and metabolism.

[29]  I. Doniach Pituitary carcinoma , 1992, Clinical endocrinology.